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Translational Relevance
The lethality of pancreatic cancer (PC) along with increasing incidence has pushed it to the forefront of the worst malignancies. Differential expression of mucins in PC makes them important diagnostic/prognostic markers. MUC4 expression in very early precursor lesions and its high specificity for tumor lesions makes it quite important for diagnostic/prognostic screening. However, its limited amount in serum diminishes its biomarker potential. To exploit the potential of mucins in the management of PC, we urgently need to explore their mechanisms of action and identify other molecules regulated by them. Herein, we report that the MUC4 mucin expressed de novo during early precursor lesions of PC regulates acute phase protein 
Introduction
Pancreatic cancer (PC), with annual incidences of 45,220 and mortality of ~38460, is among the leading causes of cancer-related deaths in the United States. More than 90% of PC patients, who at the time of diagnosis, present with unresectable disease and distant metastasis, result in a 5-year survival rate of <6% [1] . Early-stage PC symptoms are generally vague and nonspecific, which contribute to late diagnosis of the disease. The lack of early diagnostic markers and an intrinsic resistance to chemo-and radiotherapies are the major obstacles to successful management of PC at present.
Mucins present themselves as barriers between epithelial cell surfaces and their luminal milieu. Aberrant changes in mucin, both in expression and localization, are commonly observed in inflammatory conditions as well as in premalignant and malignant lesions [2, 3] . Emerging evidence indicate that the cytoplasmic tail of mucins regulates the various chronic and acute phase responses, besides providing the well-known barrier functions by forming the epithelial surface covering. The tails act as central points of interaction between extracellular milieu and cellular cytoplasm [2] . MUC4, a membrane-tethered mucin, is normally expressed in the luminal epithelial cells of the stomach, lung, trachea, cervix, and prostate, but is not expressed in normal gall bladder, liver (including intrahepatic and extrahepatic bile ducts), or pancreatic cells [4] . De novo expression of MUC4 has been observed during pancreatic cancer development and progression [5, 6] . Previously, we reported that MUC4 can alter behavioral properties of PC cells to potentiate their growth and metastasis [7] [8] [9] .
Lipocalin 2 is a low-molecular-weight glycoprotein that mediates a number of cellular processes, including apoptosis, proliferation, epithelial to mesenchymal differentiation, and matrix metalloproteinase 9 stabilization [10] [11] [12] . High levels of lipocalin 2 expression are observed in renal, breast, ovary, colon, and brain cancer cells [13] . The cDNA microarray analyses have revealed that lipocalin 2 expression in pancreatic cancer cells is 27 times higher than in normal pancreatic cells [14] , and it is among the top differentially expressed proteins during PC progression [15] . Lipocalin 2 expression differentially impact tumor growth, invasion and metastasis of PC cell depending upon differentiation status [16, 17] . Furthermore, in vitro studies have shown that lipocalin 2 enhances sensitivity of PC cell lines towards gemcitabine [17] . Recently, Raffatellu et al observed simultaneous upregulation of lipocalin 2 and MUC4 transcripts in the ileal mucosa of rhesus macaques in response to enteric S. typhimurium infection [18] . We observed that MUC4 and lipocalin 2 are also differentially expressed in pancreatic cancer tissues, from premalignant PanINs to invasive pancreatic cancer [2, 6, 15] . Furthermore, microarray analyses of MUC4 knockdown cells show multi-fold decrease in lipocalin 2 expression (unpublished results). Further, toll-like receptors are directly involved in regulation of lipocalin 2 [19] . However, the link between mucin and lipocalin 2 has remained obscure.
In the present study, we explored lipocalin 2 for its associations and regulation, and examined the clinical significance of elevated lipocalin 2 in PC. Our findings indicated that MUC4 and lipocalin 2 are coordinately expressed during the progression of pancreatic cancer and also, provided evidence for a novel regulatory mechanism of the expression of lipocalin 2 in pancreatic cancer.
Material and Methods

Cell lines, reagents and treatments
See supplementary section
Quantitative real time-polymerase chain reaction
In order to assess the transcriptional regulation of lipocalin 2 by MUC4, total RNA (2 μg) from CD18/HPAF/shMUC4 and CaPan1/shMUC4, the MUC4-knockdown cells and CD18/HPAF/Scr and CaPan1/Scr control cells was reverse-transcribed using a First Strand cDNA Synthesis Kit (Perkin-Elmer, Branchburg, NJ) and oligo-d(T) primers according to the manufacturer's instructions. Quantitative real-time-polymerase chain reaction (QPCR) amplifications were carried out with 100 ng of first-strand cDNA in 10 μl reaction volumes. The reaction mixture was subjected to a 2-step cyclic program (95°C for 10 minutes followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute) using an ABI 7500 Sequence Detection System (Applied Biosystems, Foster City, CA) with SYBR Green chemistry as per manufacturer's instructions.
The relative fold differences in gene expression were calculated using the ΔΔC T method with β-actin as a normalization control.
Sandwich enzyme-linked immunosorbent assay
DuoSet ELISA Development kit was used to measure lipocalin 2 levels in supernatants, and plasma of human as well as mouse samples as per manufacturer's instructions. This retrospective dual center study for biomarkers in PC was approved by the Institutional Review Boards (IRB) of the University of Nebraska Medical Center (UNMC) (IRB number 209-00, IRB #091-01-EP).
Samples from PC (n=91), and healthy controls (HC=24) were used to measure the lipocalin 2 amount. In case of PC patients, "post-surgery" cases include samples from patients who have undergone a pancreaticoduodenectomy, a pancreatectomy, or a pancreaticoduodenogastrectomy before the sample was drawn. All other samples, including those from patients who never had surgery during the course of their disease, were classified as "pre-surgery". Any sample drawn before the patient had undergone chemotherapy for PC was classified as "pre-chemotherapy". If the patient had ever had chemotherapy for PC, regardless of whether or not that patient was undergoing chemotherapy at the time the sample was taken, the sample was classified as "postchemotherapy". Standard curves were produced from lipocalin 2 standards provided with the kit and serially (log 2 ) diluted from 4ng/ml to 15.6pg/ml. ELISA plates were read at 450 nm and collected data were analyzed using the SoftMax Pro software program (Molecular Devices, Sunnyvale, CA). Data were analyzed using SAS statistical software version 9.2 (SAS Institute Inc, Cary, NC). Levels of lipocalin 2 were analyzed as continuous variables, while tumor grade, cancer stage, surgical status and chemotherapy status were considered to be categorical. Patient characteristics were compared between PC and control patients using ANOVA model for continuous variables and chi-square tests or Fisher's exact test wherever applicable. Biomarkers were analyzed on the natural log scale due to the skewed nature of the data. Biomarkers were compared between groups using t-tests and ANOVA models. If significant differences were found in the overall p-values from the ANOVA models then pairwise comparisons were made adjusting for multiple comparisons with Tukey's method. P-values ≤0.05 were considered statistically significant.
Confocal immunofluorescence microscopy
To study localization and effect of MUC4 knockdown on lipocalin 2, confocal microscopy was Author Manuscript Published OnlineFirst on November 15, 2013; DOI: 10.1158/1078-0432.CCR- Next, the cells were washed 5 times with PBS containing 0.05% Tween-20 and incubated with fluorescein isothiocyanate-conjugated anti-mouse and Alexa-568-conjugated anti-rabbit secondary antibodies for 30 minutes at room temperature in the dark. Nuclei were stained with 4′-6-diamidino-2-phenylindole and mounted on glass slides in anti-fade VECTASHIELD Mounting Medium (Vector Laboratories). An LSM 510 microscope (Carl Zeiss GmbH, Oberkochen, Germany) was used to perform laser confocal microscopy. Microphotographs of lipocalin 2 and MUC4 staining were taken in different channels.
Luciferase Reporter Assay
To assess the activity of lipocalin 2 promoter in MUC4 expressing and knockdown cells, cells were cultured to 60% confluence in six-well plate. Following serum starvation for 4 hrs cell were transfected with 1 µg of promoter reporter construct containing either intact NF-κB binding site 
Immunoblot Assay
Various cell types were processed for protein extraction and immunoblotting using standard procedures. Cell lysates were prepared as described previously [21] . Protein concentrations in the lysates were determined using the Bio-Rad D/C protein estimation kit. For MUC4, the lysate (20 µg each) were resolved using electrophoresis on a 2% sodium dodecyl sulfate (SDS)-agarose gel under reducing conditions. For β-actin, lipocalin 2, HER2, p 1248 HER2, AKT, pAKT, NF-κB, pNF-κB, IK-κB, and pIK-κB, SDS-polyacrylamide gel electrophoresis (PAGE; 10-12%) was performed under similar conditions. Resolved proteins were transferred onto a polyvinylidene difluoride membrane, blocked in 5% nonfat milk in PBS for 2 hrs, and subjected to standard immunodetection using specific antibodies. For immunodetection of β-actin, which was used as the internal control, an anti-β-actin mouse monoclonal antibody (Sigma) in a 1:2000 dilution of 0.1% PBS-T was used; for MUC4 immunodetection, an anti-MUC4 mouse monoclonal antibody (8G7) (diluted at 1:1000 in PBS) was used. 
Immunohistochemical analyses of MUC4 and lipocalin 2
Formalin-fixed paraffin-embedded pancreatic cancer tissue microarray slides for lipocalin 2 and MUC4 staining were provided by the Rapid Autopsy Program at the University of Nebraska Medical Center and commercial pancreatic tissue array (Accumax). These were subjected to immunohistochemical analysis as described previously [15] .
Statistical Analysis: For statistical analysis, each spot on TMA was considered an individual sample. Lipocalin 2 and MUC4 expression (positive or negative), the tissue type (normal or pancreatic cancer), and pancreatic cancer grade (well, moderately, or poorly differentiated) were considered categorical variables. These variables were compared using the Chi-square test.
Continuous variables were compared using the two-tailed Student t-test. P values less than 0.05 were considered statistically significant.
Results
MUC4 regulates lipocalin 2 expression
To explore mucin-mediated regulation of lipocalin 2, the expression of lipocalin 2 and MUC4 was evaluated in MUC4 knockdown cells and vice-versa. The regulatory role of MUC4 was assessed by its stable knocking-down in CD18/HPAF and CaPan1 pancreatic cancer cells using (CD18/HPAF/shMUC4 and CaPan1/shMUC4) were quantitated for the lipocalin 2 and MUC4 expression by immunoblot analyses (Fig. 1) . Scrambled shRNA transfected CD18/HPAF (CD18/HPAF/Scr) and CaPan1 (CaPan1/Scr) cells were used as a controls. The lipocalin 2 expression levels in CD18/HPAF/shMUC4 and CaPan1/shMUC4 cells were markedly lower than those in control cells (Fig. 1A) . Since lipocalin 2 is secretory, we also examined lipocalin 2 levels in the culture supernatants of CD18/HPAF/shMUC4 and CaPan1/shMUC4 cells and in controls by sandwich ELISA technique. The lipocalin 2 levels in the culture supernatants of CD18/HPAF/shMUC4 and CaPan1/shMUC4 MUC4-knockdown cells were significantly lower than those in the CD18/HPAF/Scr and CaPan1/Scr control cells (Fig. 1B) . In addition, confocal microscopy revealed that CD18/HPAF/shMUC4 and CaPan1/shMUC4 MUC4-knockdown cells has lower lipocalin 2 expression than CD18/HPAF/Scr and CaPan1/Scr control cells (Fig. 1C) .
Relative expression of lipocalin 2 was in correspondence with MUC4 expression. However, no alterations in MUC4 expression were observed in lipocalin 2-over-expressing cell lines (MiaPaCa/lipocalin 2 and Panc1/lipocalin 2) and lipocalin 2-knockdown cell lines (AsPC1/shlipocalin 2) (Supplementary Fig. 1 ). In addition to pancreatic cancer cells, we observed a similar phenomenon in lung cancer cell lines (data not shown). These findings suggest lipocalin 2 is a downstream target of MUC4.
MUC4 mediates its effect on lipocalin 2 by stabilizing HER2
We have previously reported that MUC4 interacts with HER2 and regulates its expression via post-translational mechanisms [22, 23] . Furthermore, we found that MUC4 stabilizes HER2 to increase the migratory potential of ovarian cancer cells [24, 25] . In breast cancer cells, studies by others have identified lipocalin 2 as a prominent downstream gene of HER2 signaling [26] [27] [28] [29] .
To determine whether MUC4 exerts its regulatory effect on lipocalin 2 in pancreatic cancer cells through HER2, we examined the expressions of HER2, its activated form pHER2, and of its downstream signaling proteins in CD18/HPAF/shMUC4 and CaPan1/shMUC4 MUC4-knockdown cells and in their respective controls ( Fig. 2A) . To reconfirm that HER2 plays regulatory role in the regulation of lipocalin 2 expression, we analyzed lipocalin 2 expression in the stable HER2-knockdown clones (CD18/HPAF/shHER2 and CaPan1/shHER2). HER2 and MUC4 knockdown showed a significant reduction of lipocalin 2 expression in CD18/HPAF and CaPaN1/shHER2 cells, compared to that in scrambled shRNA-transfected cells (Fig. 2B) . 
MUC4 mediates its effect on lipocalin 2 expression via the HER2/PI3K/AKT/NF-κB pathway
We analyzed the regulation of MUC4-and HER2-downstream actors in the knockdown clones of CD18/HPAF and CaPan1 cells. Immunoblot analyses of AKT and pAKT expression in CD18/HPAF/shMUC4 and CaPan1/shMUC4 cells revealed that pAKT (Ser473) activation levels were significantly reduced, while the levels of expression of total AKT remained unchanged.
Since HER2 mediates its effect on AKT through PI3K pathway, we sought to assess the role of AKT in lipocalin 2 regulations in pancreatic cancer cells by treating CD18/HPAF and CaPan1 cells with the PI3K inhibitor LY294002. Immunoblot analyses revealed that when a standard dose of LY294002 (50 µM) was used, it resulted in a time-dependent decrease in pAKT and lipocalin 2 expression in CD18/HAF and CaPan1 cells (Fig. 2C&D) , which confirmed that AKT is involved in MUC4-mediated regulation of lipocalin 2 expression.
To identify the downstream mechanisms of MUC4-mediated regulation of expression of lipocalin 2 in PC cells, we employed real time quantitative PCR analyses to measure lipocalin 2 mRNA levels in CaPan1/shMUC4 MUC4-knockdown cells and in scrambled shRNAtransfected control cells. These experiments revealed that lipocalin 2 mRNA levels were higher in the scrambled cells than in the MUC4 knockdown cells (Fig. 3A) . A similar trend was observed for MUC4 mRNA (Fig. 3A) .
In silico analysis of lipocalin 2 promoter by TRESS indicated the presence of a NF-κB binding site (Fig. 3B) . To delineate the role of NF-κB in the regulation of lipocalin 2 expression, CD18/HPAF MUC4 scrambled and knockdown cells were transfected with luciferase constructs of the proximal region of lipocalin 2 promoter with 900 bp of wild type lipocalin 2 (pGL3-lipocalin 2-267) containing either an intact NF-κB binding site, or an inactivating mutation in the NF-κB binding site, along with renilla luciferase. When compared to the knock-down cells, relative luciferase activity was significantly higher in the CD18\HPAF\Scr cells (Fig. 3C) . To determine whether MUC4 regulates lipocalin 2 expression through NF-κB, we assessed the levels of total IK-κB and pIK-κB in MUC4-and HER2-knockdown clones of CD18/HPAF and CaPan1 cells and found that knockdown of either MUC4 or HER2, resulted in decreased IK-κB phosphorylation (Fig. 3D&E) . To further characterize the role of NF-κB in MUC4/HER2-mediated upregulation of lipocalin 2, we treated CaPan1 cells with Bay 11-7082, which inhibits IκBα degradation and also, blocks the translocation of NF-κB from the cytoplasm to the nucleus. This treatment decreased lipocalin 2 expression levels in a time-and dose-dependent manner (Fig. 3F,   supplementary Fig. 2) , confirming that MUC4 regulates lipocalin 2 expression in pancreatic cancer cells by stabilizing HER2, which in turn activates NF-κB through the activation of pAKT.
Clinical correlation of MUC4 and lipocalin 2
We observed that MUC4 regulates the expression of lipocalin 2 through PI3K-AKT-NF-κB pathway. Both MUC4 and lipocalin 2 show elevated expression during the progression of pancreatic cancer [6, 15, 30] . To investigate the association between MUC4 and lipocalin 2 during the pathogenesis of pancreatic cancer, we performed immunohistochemical staining on FFPE (formalin fixed paraffin embedded) tissue sections with the mouse anti-MUC4 monoclonal antibody 8G7 and rabbit anti-lipocalin 2 polyclonal antibodies. Interestingly, as can be seen in (Fig 4A-H) .
We observed no MUC4 staining and only weak lipocalin 2 staining in normal pancreatic tissue.
The observed staining for MUC4 was mainly membranous staining while both cytoplasmic and membranous staining was observed for lipocalin 2. These results suggest that lipocalin 2 and MUC4 are concomitantly overexpressed in pancreatic cancer. Further, we analyzed MUC4 and lipocalin 2 staining in primary and metastatic (lung and lymph nodes) pancreatic cancer specimens obtained through a rapid autopsy program. Qualitative analyses revealed a significant positive correlation between lipocalin 2 and MUC4 expression in human and mouse tissue specimen ( Table 1) . Similarly, the percentages of MUC4-positive metastasis specimens with lipocalin 2 expression (78% for the lungs; and 100% for the lymph nodes) were higher than those of MUC4-negative specimens (22% for the lungs, and 0% for the lymph nodes). Furthermore, Spearman correlation coefficient analyses indicated significance for coordinated expression of lipocalin 2 and MUC4 in both primary and metastatic cases.
In the absence of a sensitive test to detect MUC4 in the serum for determining the clinical significance of the above observation, tissue expression of MUC4 was compared with serum levels of lipocalin 2. To this end, we examined these molecules in the Kras 
progression mouse model of PC, which closely mimics the early developmental stages of PC.
Interestingly, MUC4 expression in pancreatic tissues in this early progression model (Fig. 4I-N) correlated strongly with elevations in the levels of lipocalin 2 in the serum samples at different weeks of disease progression (Fig. 4O) (Spearman correlation coefficient 0.98; p-value=0.045).
Furthermore, lipocalin 2 in serum of double transgenic animals increased progressively with disease advancement in comparison to control animals (p<0.0001). On the log scale, on average lipocalin 2 amount in double transgenic animal were 1.43 times (95% CI: 1.01-1.86) than in the controls.
In the absence of a robust diagnostic/prognostic marker for PC, the diagnostic and prognostic significance of lipocalin 2 was assessed by analyzing its concentration between PC and healthy control subjects through sandwich ELISA. We found that PC patients have significantly higher lipocalin 2 levels (148±13.18 ng/ml) than control patients (73.27±4.9 ng/ml, p-value=0.014) (Fig. 5A) . The prognostic significance of lipocalin 2 was indicated by the higher pre-chemotherapy levels of lipocalin 2, compared to post-chemotherapy levels (p=0.060) (Fig.   5B, supplementary table 1) . Lipocalin 2 levels were also found to be higher in welldifferentiated tumor in comparison to poorly differentiated tumors (supplementary Fig. 3 ). For evaluating response to surgery, multiple samples withdrawn from some patients were used to fit mixed effect model. This model allowed the inclusion of all the data (repeated measurements from same patient). However, no significant differences in lipocalin 2 levels were observed in pre-surgical and post-surgical cases (supplementary Fig. 3A, supplementary table 1) . Further, pre-and post-operative levels of lipocalin were assessed in individual patients (n=7). Of the seven patients, 3 had a decrease in the mean levels of lipocalin 2 post-surgery while 4 had an increase (supplementary Fig. 3B ). The analyses done using this model did not change the performance of lipocalin 2 with regard to surgical status.
Discussion
The differential expression of trans-membrane mucin MUC4 is observed during pancreatic cancer progression. The present study investigated the molecular mechanisms of lipocalin 2 regulation by the MUC4 mucin in PC, and its potential diagnostic and prognostic significance. Besides the classical functions performed by mucins, including hydration, lubrication and protection of exposed surfaces, the transmembrane mucin MUC4 has been indicated to play roles in modulating cell proliferation, apoptosis, morphology, and metastasis of neoplastic cells [7, 9, 22, 24, 31] . In previous studies, we observed specific and differential expression of lipocalin 2 in PC cells but not normal pancreatic cells. In particular, we found low lipocalin 2 expression levels in normal pancreatic tissue and inflamed pancreatic tissue but very high levels in early dysplastic lesions (i.e., PanINs), and it may be a feature even earlier, as studies with PanIN I report [15] .
Using a high-density cDNA microarray, Han et al. found that the upregulation of lipocalin 2 expression in neoplastic cells was 27 times higher than that in normal pancreatic cells [14] .
Terris et al. identified lipocalin 2 as a marker of intraductal papillary mucinous neoplasm, a precursor lesion for invasive carcinoma [32] . Moreover, Iacobuzio-Donahue et al., using cDNA microarrays to examine the global gene expression patterns in pancreatic adenocarcinoma cells, also found that lipocalin 2 was significantly overexpressed in pancreatic cancer cells [33] . Wang et al used anti-lipocalin 2 antibodies for in vitro and in vivo imaging of human pancreatic cancer cell but its secretory nature limited the utility [34] . IHC analyses of MUC4 and lipocalin 2 in PC tissues revealed that the expression of these genes was elevated during PC development [15, 35] .
To examine the pathobiological roles of MUC4 and lipocalin 2 in pancreatic cancer, we sought to determine whether MUC4 regulates expression of lipocalin 2 or vice-versa in the present study. Paradoxically, knockdown studies revealed that MUC4 had a strong downregulatory effect on lipocalin 2 in cell lysates and spent culture medium. Further, we found that lipocalin 2 and MUC4 were concomitantly expressed in PanIN1-III lesions. Given the absence of MUC4 from normal pancreatic cells and the de novo expression at very early stages of PC and its suggested roles, including its oncogenic ability (causing oncogenic transformation of NIH3T3 cells), the ability of resisting apoptosis, and the stabilization of the receptor tyrosine kinase HER2, we sought to determine whether lipocalin 2 expressions is regulated by MUC4.
MUC4 is an intra-membrane ligand and activator of HER2 and thus facilitates the dimerization of HER2 with other ErbB receptors [9, 36, 37] . Researchers have detected the MUC4/HER2 complex in many tissues in which MUC4 is normally expressed [38, 39] and in various tumors and cancer cell lines that aberrantly overexpress MUC4 [22, 23] . Silencing in expression of its phosphorylated form (pY 1248 -HER2) [22] . The present study showed that expression of lipocalin 2 was lower in CD18/HPAF/shMUC4 and CaPan1/shMUC4 MUC4-knockdown cells, and in CD18/HPAF/shHER2 and CaPan1/shHER2 HER2-knockdown cells than in the controls. Similar to the present study's findings of HER2 mediated regulation of lipocalin 2, HER2 was earlier reported to induce lipocalin 2 expression in breast cancer cells [28] . Moreover, the rat homologue of lipocalin 2 (known as Neu-regulated lipocalin) is a lipocalin that is overexpressed in rat mammary cancer induced by activated neu (HER-2/CerbB2) [35] . [12] . They found that lipocalin 2 gene expression in the secretome of NF-κB-expressing FRO thyroid carcinoma cells were higher than that in NF-κB-null FRO cells [12] . Another study of lipocalin 2 promoter revealed the presence of a cis-binding element for NF-κB [42] . In addition to MUC4, other factors including HER2, EGFR and KRAS are also involved in lipocalin 2 regulation in PC by impacting NF-κB activity [16] . Taking a cue from the previous 
dependent and an effect varies deepening upon cell type, microenvironment as well as tumor burden. Accordingly, it can be suggested that various assets of lipocalin 2 i.e. multifaceted role, unique regulation (MUC4, Ras, EGF, IL-10 and TLRs) and various sources (produced by both tumor and immune cells) impacts it effects on tumor growth, progression, invasion, and metastasis in multiple ways [45] [46] [47] [48] . Accordingly, the data need to be interpreted carefully prior to its clinical use in oncolytic viruses harboring cancer targeting genes [49] . Further, the finding from the present study will be of high impact in upper respiratory (oral, oesophageal and lung) infection where MUC4 is heavily expressed and might be involved in regulating in body's response to harmful changes in extracellular milieu.
In conclusion, the present study provides evidence that MUC4 regulates lipocalin 2 expression in pancreatic cancer cells as it stabilizes HER2 that activates the downstream PI3K/AKT/NF-κB pathway (Fig. 6) . The clinic-pathological studies suggested lipocalin 2 may be a potential biomarker for PC. These results emphasize that mucin covering are not inert layers .9) . B, Lipocalin 2 levels were compared between pre-(n=62) vs. postchemotherapy (n=106) samples using mixed-effects models. Pre-chemotherapy levels of lipocalin 2 were found to be higher than post-chemotherapy levels (p=0.060). C, Lipocalin 2 levels were marginally decreased with differentiation status of tumor although differences were not significant. 
